Molecular biology in head and neck cancer.
Major changes in the treatment of head and neck cancer are possible today because of the knowledge that we have on the molecular biology of these tumors. Different pathways are active in the development of this cancer and field cancerization is a major problem for the cure in early stage disease. Epidermal growth factor signal transduction pathway is now the principal target for this disease. New therapeutic strategies such as monoclonal antibodies and small molecules have appeared, however no more than 20% of the patients have objective responses with these therapies. Consequently, new alternatives of treatment in the basis of the understanding of molecular biology are necessary to increase the number of patients that can be cured in the future.
Hitt
Ricardo
R
Division of Medical Oncology. Hospital Universitario 12 de Octubre. Madrid. Spain. rhitt@h12o.es
Echarri
María José
MJ
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000628:therapy; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D018450:Disease Progression; D015195:Drug Design; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000502:physiology*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D018773:Genes, erbB-1; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000532:radiotherapy; D006801:Humans; D008297:Male; D009154:Mutation; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D017384:Sequence Deletion; D015398:Signal Transduction
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D066246:ErbB Receptors